Cabazitaxel: A Novel Drug for Hormone-Refractory Prostate Cancer

Author(s): Manav Malhotra, Richa Dhingra, Tina Sharma, Aakash Deep, Balasubramanian Narasimhan, Priyanka Phogat, Prabodh Chander Sharma

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 13 , Issue 6 , 2013

Become EABM
Become Reviewer


Cabazitaxel has recently been approved by FDA for the treatment of docetaxel resistant hormone-refractory prostate cancer. It has been developed by Sanofi-Aventis under the trade name of Jevtana. It is given in combination with prednisone/prednisolone and has passed the clinical trial over well-known drug mitoxantrone. This drug is a microtubule depolymerization inhibitor, which can penetrate blood brain barrier (BBB). The FDA granted fast track designation to this drug in November 2009 and thereafter, new drug application submission was done in March 2010. Priority review to this drug was granted in April 2010 and finally in July 2010 it was approved by FDA. It is available in the form of injection in the dose of 60 mg/1.5 mL, which should be diluted prior to its use by the diluents supplied along with the injection. It is a second-line drug and has proven to be effective in patients experiencing docetaxel based treatment failure.

Keywords: Prostate cancer, Jevtana, Sanofi-aventis, Taxanes, Cabazitaxel, XRP-6258

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 03 April, 2013
Page: [915 - 920]
Pages: 6
DOI: 10.2174/1389557511313060011
Price: $65

Article Metrics

PDF: 14